Myda Advisors LLC Autolus Therapeutics PLC Transaction History

Myda Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.04 - $4.68 $30,600 - $70,200	-15,000 Reduced 13.04%	100,000 $283,000
Q1 2022 May 13, 2022	SELL	$3.52 - $5.46 $35,200 - $54,600	-10,000 Reduced 8.0%	115,000 $480,000
Q4 2021 Feb 11, 2022	SELL	$5.1 - $7.0 $239,460 - $328,671	-46,953 Reduced 27.31%	125,000 $649,000
Q3 2021 Nov 12, 2021	BUY	$5.32 - $7.37 $462,589 - $640,843	86,953 Added 102.3%	171,953 $1.13 Million
Q2 2021 Aug 13, 2021	BUY	$4.78 - $7.96 $406,300 - $676,600	85,000 New	85,000 $564,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $205M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Myda Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Myda Advisors LLC with notifications on news.